Inhaled drug company MannKind Corporation has announced the appointment of Kevin Kaiserman as VP, Medical Affairs and Safety. Kaiserman, a pedicatric endocrinologist, was most recently in private practice.
The company markets Afrezza inhaled insulin, which was approved by the FDA in 2014, and is partnered with United Therapeutics on development of a treprostinil DPI for the treatment of pulmonary arterial hypertension. Earlier this year, MannKind announced that it would refocus its R&D efforts on the treatment of COVID-19, in particular, a DPI development project with Immix Biopharma. In July 2020, the company announced the appointment of Alejandro Galindo as Chief Commercial Officer.
MannKind CEO Michael Castagna commented, “As a board-certified pediatric endocrinologist, Kevin brings significant expertise in the field of type 1 diabetes, and is an integral addition to MannKind as we expand our medical affairs capabilities and advance our pediatrics program. His deep expertise in continuous glucose monitoring and insulin delivery, coupled with his lengthy experience in educating the endocrinology community, will be instrumental in moving our medical initiatives forward and supporting the effort to expand our Afrezza user base.”
Kaiserman said, “I’m thrilled to join MannKind during this exciting time of expansion. Afrezza is a novel treatment option that provides mealtime control and flexibility for adults living with type 1 and type 2 diabetes. I look forward to working with my colleagues across the country to study this therapy in pediatrics and hope to bring the benefits of Afrezza to children and adolescents living with diabetes. I’ve seen the rapid rate of innovation around diabetes management over the past decades and am honored to lead the medical team at a company that is changing the way people living with diabetes take control of their health.”
Read the MannKind Corporation press release.
